2009 Medical Innovation Summit

The Summit will bring together more than 900 leaders from throughout the healthcare industry to learn about the latest innovations in cancer care, exchange perspectives and gain actionable insights.

This year's Summit will highlight new technologies in the oncology field, giving attendees access to the latest innovations in cancer therapy, diagnostics and management. Drawing international CEOs, leading venture capitalists, entrepreneurs, renowned physicians and top technologists, the summit will examine in detail the hottest new cancer technologies, prospects for new cancer innovation, and forces shaping the markets for new cancer technology.

"This Medical Innovation Summit will bring together some of the most important thought leaders in the world of healthcare, cancer technology and venture investment. In light of the current economy, it is more important than ever to discuss the future of innovation and our increased need to support new technology," said Christopher Coburn, Executive Director of Cleveland Clinic Innovations. "Everyone has been touched in some way by cancer, and we are excited to highlight the many clinical innovations taking place in this field." sample vials

The 2009 Medical Innovation Summit will feature more than 40 international leaders, including CEOs Sam Palmisano, IBM; Daniel Vasella, M.D., Novartis; David Brennan, AstraZeneca; Richard Clark, Merck; Fred Hassan, Schering-Plough; Greg Lucier, Life Technology, FDA Commissioner Margaret Hamburg, M.D.; network correspondent Maria Bartiromo, CNBC; and the CEOs and venture investors of numerous emerging technology companies.

Summit highlights will include live surgeries, Meet the Doctor Roundtables, and sessions featuring: "Key Issues in new Cancer Technologies," "The Market for Consumer Genotyping in Oncogenomics," "the Grand Challenges in Contemporary Cancer Treatment," "The Revolution in Radiotherapy Technology," "Corporate Venturing in a time of Financial Crisis," "Maximizing Innovation in Pharma," and "Enabling New Technologies and New Therapies," and much more.